Breast Mammogram and Tissue Study
Women whose mammograms show a lot of dense areas are more likely to develop breast cancer and to have cancers that are missed by mammograms.
It is unclear why some factors lead to having dense breasts and why having dense breasts increases the risk of developing breast cancer.
To determine why some women s breasts look dense on mammograms.
To determine what types of cells and tissues make up dense areas of breasts and why these tissues may be more likely to become cancerous.
Women between 40 and 65 years of age who have not had breast cancer or received medicines or radiation for any type of cancer and who are scheduled to undergo a breast biopsy.
This study is conducted at the University of Vermont, in collaboration with the NCI.
Participants undergo the following:
- Review of their medical records collected over the last 2 years by the Vermont Mammography Registry.
- Participation in a short telephone interview.
- Height and weight measurement.
- Testing of biopsy tissue collected for diagnosis or treatment.
- Future contacts regarding health status for up to 10 years, including review of additional mammograms, removed tissues, questionnaires and medical records collected by the Vermont Mammography Registry during the 10-year study.
Participants may also undergo the following optional procedures:
- Provide a mouthwash sample for genetic testing.
- Provide a blood sample to test for markers of dense mammograms or breast cancer.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Breast Radiology Evaluation and Study of Tissues (Breast) Stamp Project|
- Breast Cancer [ Time Frame: Enrollment ] [ Designated as safety issue: No ]
- Mammographic density [ Time Frame: Enrollment and over 10 years of follow-up ] [ Designated as safety issue: No ]
|Study Start Date:||May 2007|
High breast density and aging are the strongest risk factors for sporadic breast cancer among women. Although glandular epithelium contributes to mammographic density, non-epithelial tissue components represent its major determinants: adipose tissue is radiolucent and fibrous tissue is dense. The hypothesis is that epidemiologic factors associated with elevated breast density alter the breast microenvironment (ME) (defined as all cells and structures surrounding luminal glandular cells including: myoepithelial cells; basement membrane, stromal fibroblast and myofibroblasts; endothelial cells and pericytes; inflammatory cells, collagens, matrix proteins, growth factors, hormones, and other biochemical components) in a manner that enhances dysregulated proliferation of breast epithelium and ultimately cancer. Specifically, the Investigators propose that epidemiologic factors that lead to increased exposure to hormones and inflammatory mediators alter the ME, leading to both increased breast density and cancer. The critical importance of the ME in carcinogenesis is supported by experimental and clinical data showing that epithelial abnormalities alone are generally insufficient for cancer development without concurrent changes in the ME. The primary aim of this pilot study is to demonstrate the feasibility of collecting the data needed to elucidate the biologic mechanisms that mediate the substantial breast cancer risk associated with high mammographic density. Specifically, the Investigators will develop, fine tune, and validate a complex cross-sectional study protocol to collect risk factor data and biological specimens (blood, buccal cells, tissue fluids, and tissue) required to discover mechanisms and biomarkers that link high mammographic density (as measured quantitatively using computerized methods) to breast cancer risk. They will enroll 250 women between the ages of 40 to 65 years undergoing a radiologically guided biopsy at the University of Vermont, the largest center within the Vermont Breast Cancer Surveillance System (VBCSS), to participate in this pilot study of mammographic density.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00475761
|United States, Vermont|
|University of Vermont|
|Burlington, Vermont, United States, 05405|
|Principal Investigator:||Gretchen Benson, Ph.D.||National Cancer Institute (NCI)|